Objective: This study aims to evaluate patterns in actigraphy-defined sleep measures across the menstrual cycle by testing the hypothesis that sleep would be more disrupted in the premenstrual period (ie, within the 14 d before menses).
S hifts in hormone levels and changes in hormone patterns across the menstrual cycle have been hypothesized to be associated with transient alterations in sleep patterns. In menstruating young adult women, the menstrual cycle is characterized by major shifts in hormone levels occurring around the midcycle, with marked increases followed by declines in estradiol and, subsequently, marked increases in gonadotropins, especially luteinizing hormone (LH). After ovulation, the preovulatory increase in estradiol is accompanied by a 3-to 10-fold increase in progesterone levels. In the week preceding menstruation, progesterone and estradiol levels fall. However, in midlife women, anovulatory events become increasingly frequent, and the proportion of days before and after the LH surge begins to shift, 1<3 leading to questions concerning the role of reproductive aging in the reporting of sleep disturbances in women. 4, 5 Prior studies have reported sleep disturbances during the premenstrual week and during the first few days of menstruation compared with other times in the menstrual cycle. 6, 7 The National Sleep Foundation's Sleep in America survey (2007) indicated that 25% to 33% of menstruating women complained of sleep disturbances during the premenstrual week or during menses; women who reported severe premenstrual symptoms also experienced symptoms of insomnia and daytime sleepiness. 6 Smaller studies of women with premenstrual mood disorders have identified substantial sleep disturbances, including either hypersomnia or insomnia, during the premenstrual period. 8, 9 The extent to which findings from these studies can be extrapolated to midlife women as they approach menopause remains in question, thereby limiting our understanding of the extent to which increased sleep disturbances in midlife women are associated with alterations in menstrual cycles and hormone dynamics. 4, 10 Methodological issues (eg, statistical: nonparametric functional form, between-participants variations, and within-participant variations) have made the development of an informative body of literature challenging. 11 Many studies have used polysomnography (PSG) data to study sleep patterns objectively, but few studies have characterized sleep alterations across the entire menstrual cycle. 12 Appropriately designed studies with multiple nights of PSG throughout a menstrual cycle are costly, are difficult to implement, and typically result in studies with small sample sizes of highly selected groups.
Actigraphy provides unique real-time information on sleep and activity and has been widely used to document sleepwake patterns objectively. 13, 14 Therefore, wrist actigraphy data acquired during the Study of Women's Health Across the Nation (SWAN) Sleep Study were used to generate daily sleep measures (sleep efficiency and total sleep time) and a measure of movement (mean activity score) across a menstrual cycle in midlife women. We hypothesized that the mean profiles of these sleep measures would change, consistent with the different phases of the menstrual cycle, particularly the premenstrual period, which is a time of notable sleep complaints in midlife women.
METHODS

Study population
Data for this report were obtained from the SWAN Sleep Study, a comprehensive study of sleep nested within the ongoing longitudinal SWAN cohort and conducted in four of seven SWAN clinical sites from 2003 to 2005, across a time frame that overlapped with the fifth, sixth, and seventh annual core SWAN assessments that have been described in detail. 15 
SWAN design and participants
SWAN is a multiethnic, community-based, multisite cohort study of the menopausal transition. A total of 3,302 women were enrolled for longitudinal evaluation using a communitybased survey conducted at seven sites: Boston, MA; Chicago, IL; Detroit area, MI; Los Angeles, CA; Oakland, CA; Newark, NJ; and Pittsburgh, PA. Each site recruited a sample of white and minority women. Eligibility criteria were as follows: aged 42 to 52 years, not pregnant, not using exogenous hormones in the 3 months before interview, with an intact uterus and at least one ovary, with at least one menstrual period in the 3 months before baseline interview, and self-identifying as white or as the site's designated racial/ethnic group. Each site's institutional review board approved the study protocol, and all women gave a written informed consent form to participate.
SWAN baseline and follow-up assessments consisted of detailed questions about medical, reproductive, and menstrual history, lifestyle and psychosocial factors, physical and psychological symptoms, vasomotor symptoms, and additional factors that might be related to menopause and sleep. Measurements of height and weight were obtained using a common protocol.
SWAN Sleep Study design and participants
Three hundred seventy women aged 48 to 59 years were enrolled from the Chicago, Detroit area, Oakland, and Pittsburgh SWAN sites, including 328 premenopausal and perimenopausal and 42 postmenopausal African-American, white, and Chinese women. Two women did not complete the SWAN Sleep Study. Eligibility for the SWAN Sleep Study was based on information from annual core SWAN assessments. Initially, women who were defined by the core SWAN as premenopausal or perimenopausal were recruited; later, postmenopausal women were included. Women who had hysterectomy (G1%) or were using hormone therapy (approximately 23% of the cohort) were excluded. Also excluded were women who were being treated for cancer or those who worked night or rotating shifts (exclusion rates for these factors were between 1% and 3%).
Overall, approximately 30% of eligible participants declined to participate in the SWAN Sleep Study. SWAN Sleep Study participants did not differ markedly from other SWAN participants at the four SWAN Sleep Study sites with regard to self-assessed sleep quality, race, self-reported health status, or proportion with depressive symptoms. 4, 16, 17 
SWAN Sleep Study protocol
Sleep measures included wrist actigraphy, PSG, and sleep diaries. Among those women who were still menstruating, the sleep protocol was initiated within 7 days of the onset of menses. In-home PSG studies were conducted on the first three nights of the protocol, whereas wrist actigraphy and sleep diary data were collected daily for an entire menstrual cycle or 35 days, whichever was shorter.
Bend, OR), and data were analyzed with the Actiware software (versions 3.4 and 5.0; Mini-Mitter Co Inc, Bend, OR). Batteries were replaced around the 14th day of recording, and data were collected for the period up to the next menstrual bleed or up to 35 days, whichever came first. Participants were asked to wear the actigraph 24 hours/day, removing it only for bathing or swimming. When the actigraph was removed, the times were noted on the daily diaries. The two questions in the bedtime diary were as follows: (1) Today, I took off my actigraph (yes or no?). (2) If yes, when were time off and time on? Electronic data were sent to the University of Pittsburgh study site for processing, evaluation of data quality, and scoring. Recording procedures and staff training were designed to reduce the incidence of missing data. Self-reported data were checked and verified in the presence of participants, and procedures were implemented to prevent loss of actigraphy data. A study assessing reproducibility, inter-rater reliability, and intrarater reliability between two scorers was performed. For inconsistent data, actigraphy variables were further checked graphically by examining logic and ranges. If extreme values were found, the corresponding diary data were further examined to identify root causes. Those extreme values were excluded from the analysis. In the data preparation stage, fragmentation index is used to screen the data. The fragmentation index is an index of restlessness during sleep, with higher values indicating more restlessness, and is calculated by summing the number of minutes with movement (expressed as a percentage of the immobile phase). 18 Actigraphy data were recorded continuously, and total activity count was determined using 1-minute sampling epochs. Actigraphy-based sleep-wake variables were determined using the Actiware software, with total activity counts above the threshold sensitivity value of 40 counts per epoch. In the Actiware software, Bsleep start[ represents the time of sleep onset and is determined by the first 10-minute period in which no more than one epoch is scored as mobile. BSleep end[ represents the time of sleep termination and is determined by the last 10-minute period in which no more than one epoch is scored as mobile.
The actigraphy variables reported herein include the following: (1) total sleep time (minutes), which reflects the sum of those epochs between sleep start and sleep end from the diaries that were designated as Bsleeping[; (2) sleep efficiency (%), which is an index of the amount of time in bed actually spent sleeping and is determined by dividing total sleep time by the time in bed, multiplied by 100; and (3) mean activity score, which reflects the magnitude of activity on a per-epoch basis during sleep and is determined by dividing total activity score by the number of epochs during the assumed sleep period (the interval between actigraphically defined sleep start and actigraphically defined sleep end).
Sociodemographic and health-related variables from the core SWAN
Sociodemographic and health-related variables from the core SWAN were collected at the baseline and annual core SWAN assessments. Information about age, marital status (single/never married, married or living as married, separated/widowed/ divorced), educational attainment (high school graduate or less, some college, college graduate, graduate studies), and selfreported health status (poor, fair, good, very good, excellent) was obtained from questionnaires. A three-level response to a question about difficulty paying for basics, including food, shelter, and health care (very difficult, somewhat difficult, not very difficult), was used as an indicator of financial strain.
The Perceived Stress Scale, which reflects the degree to which situations in one's life were appraised as stressful, was summarized from four interview questions (with scores between 1 and 5 for each question) 19 and treated as a dichotomous variable (with cutoff points at G15 and Q16). Body mass index (BMI) was computed as weight in kilograms divided by height in meters squared and was treated as a dichotomous variable (nonobese vs obese; cutoff at 30 kg/m 2 ). 20 Study site was included in statistical models as an indicator variable, in combination with race/ethnicity variable responses.
Menopause-related variables
Menopause-related variables were obtained from the core SWAN annual visit that preceded the SWAN Sleep Study. Using menstrual bleeding criteria, we classified participants into one of the following four categories: premenopausal (no change in menstrual bleeding regularity), early perimenopausal (menses in the preceding 3 mo with increased bleeding irregularity in the previous 12 mo), late perimenopausal (menses in the previous 12 mo but not in the previous 3 mo), and postmenopausal (12 mo of amenorrhea). 21<23
Variables from sleep study, questionnaires, or daily sleep study diaries
The first night of the sleep protocol also included instrumentation to screen for the presence of sleep-disordered breathing. Apnea-hypopnea index (AHI) is based on the number of apnea events plus the number of hypopnea events per hour of sleep. 24 Depressive symptoms were evaluated using the 16-item Inventory of Depressive Symptoms, which was administered on the last day of the SWAN Sleep Study protocol. 25 Data analysis with the Inventory of Depressive Symptoms was based on scores in which the contribution from the four sleeprelated items had been removed.
The SWAN Sleep Study diaries were completed twice a day: at waketime and at bedtime. Women were classified as having vasomotor symptoms on a given day if they reported an affirmative response to the question about cold sweats, hot flashes, or night sweats on their daily diaries. 26 In the morning (waketime) diary, women recorded mood and behavioral symptoms, including how rested, blue/down, and anxious/ tense they felt, and whether they had experienced worries (coded as present or absent) during the night. In the bedtime diary, daytime fatigue/feeling tired and pain/discomfort were recorded (coded as present or absent).
Daily use of medications affecting sleep (both prescription and over-the-counter medications) was recorded at SWAN Sleep Study protocol inception and on daily diaries. This was coded according to the World Health Organization Anatomical Therapeutic Chemical classification. 27 In this report, medications affecting sleep were those products associated with the following Anatomical Therapeutic Chemical classification codes: N02A (opioids), N03A (antiepileptics), N05B (anxiolytics), N05C (hypnotics and sedatives), N06A (antidepressants), and R06A (antihistamines). Daily use of medications affecting sleep was dichotomized as present or absent. Daily exercise was defined according to a four-level response (0, none; 1, light; 2, moderate; 3, heavy). Daily responses about smoking frequency, alcohol consumption, and caffeine consumption were determined from the sleep diaries. Current smokers were those who reported occasional smoking (at least seven cigarettes in the 2-wk period initiated by the sleep protocol). Sleep diary variables were treated as time-varying covariates in the analysis.
Data analyses
To be eligible for analyses, women had to satisfy the following criteria: (1) had actigraphy and diary data after day 14 of the menstrual cycle and extending to the next menses or up to 35 days, whichever came first, with a minimum of 10 observations; (2) were still menstruating (premenopause, early perimenopause, and late perimenopause); and (3) had completed sleep diaries, allowing us to determine the onset of the subsequent menstrual bleeding episode, daily sleep start, and sleep in parallel with their actigraphy data. Of the 370 women enrolled in the SWAN Sleep Study, 347 provided wrist actigraphy information and the appropriate accompanying daily diaries necessary for deriving the sleep variables and for documenting menstruation. Of these, 285 women were still menstruating. Thirteen women were excluded because more than 50% of their observed values for the fragmentation index, mean activity score, or actual waketime were zero, which was not a valid value for a participant wearing a functioning actigraph. For comparisons of follicular and luteal phases, an additional 109 women were excluded because they had no clearly identified first day of the menstrual cycle or they had no data after day 14 of the menstrual cycle. Overall, 163 women met the criteria and contributed 3,047 observations (mean, 18.7 d per woman) to the analysis. The mean (SD) cycle length was 25.9 (6.8) days.
To address the variability in menstrual cycle lengths, we standardized the menstrual cycle data uniformly to a reference 28-day period by weighting the data through a scale factor 28/cycle i , where cycle i was the actual cycle length for the ith woman. 28, 29 The standardized data were segmented into four 7-day weekly units. Information from the first week (days G7) was not included in the analyses, as other components of the protocol, such as habituating to overnight sleep assessments, may have disturbed actigraphy-assessed sleep. 30 
Statistical methods
Univariate statistics, including means (SDs) and medians (interquartile ranges [IQRs]), were computed for continuous variables, and frequencies were determined for categorical variables. Variables with highly skewed distributions were transformed or categorized. For modeling, the actigraphybased variable mean activity score, as well as BMI and AHI, was transformed using natural logarithm. Statistical significance was based on P values from two-sided tests and defined as P G 0.05.
First, sleep measures were plotted for 163 women to explore the day-to-day patterns of change across a complete menstrual cycle. The analysis showed that the relationships between actigraphy outcomes and time (day of menstrual cycle) were nonlinear across time and could not be appropriately modeled by quadratic or cubic terms. To allow for flexibility in the functional form of sleep measures, we used semiparametric stochastic mixed-effects models with smoothed splines to fit the mean profiles across time. 29 As an extension of linear mixed models for longitudinal data, this method uses parametric fixed effects to represent covariate effects, a smooth function to model time effects, and random effects and stochastic processes to model within-woman correlations. Thus, this method is particularly powerful for modeling longitudinal data and biological signals with flexible functional forms without the assumption of parametric trend (eg, linear or quadratic form). Bootstrapping was used to fit upper and lower 95% CIs around the mean profile. 31, 32 To compare segment-specific differences in sleep measures, we used a piecewise linear mixed-effects model by placing nodes at the points corresponding to days 14 and 21 to generate weekly segments. The day 14 node was approximately midcycle, and it was assumed that periovulatory events could be demonstrated by comparing means and slopes from the second week (8-14 d) with means and slopes from the third week (14-21 d). Similarly, a node was placed on day 21, and it was assumed to represent the initiation of the premenstrual period (fourth week, 21-28 d). The slopes and leastsquares means were calculated for each of the 3 weeks. F tests from repeated-measures analysis of variance with orthogonal contrast were used to assess the importance of changes in the least-squares means and slopes of these weekly segments (see Appendix I in the Supplemental Digital Content, http://links.lww.com/MENO/A99).
Covariates that were eligible for inclusion in all models included chronological age, BMI, menopause status, health status, perceived stress, race, financial strain, marital status, education, and site as fixed variables. Time-varying variables from the SWAN Sleep Study included AHI, symptoms of depression, smoking, vasomotor symptoms, exercise, alcohol consumption, caffeine consumption, and use of medications affecting sleep. Covariates were retained in the final models only if they were statistically significant at the P G 0.05 level. Interaction terms with the segment variable and each covariate were evaluated in the models. SAS 9.3 and Macro facilities (SAS Institute, Cary, NC) were used to perform statistical analyses and to plot the findings.
The median (IQR) BMI was 27.6 (8.9) kg/m 2 . Women selfidentified as African American (35.6%; n = 58), white (47.9%; n = 78), or Chinese (16.7%; n = 27). About 16% of women reported smoking, whereas 62.1% of women reported having any vasomotor symptoms during their observed menstrual cycle.
Across the standardized menstrual cycles (days 8-28), the median actigraphy-assessed sleep efficiency was 82% (highly variable with an IQR of 15.5%), which was slightly lower than the normally expected value of 85%. The median total sleep time was just more than 6 hours per night (median [IQR], 363
[107] min). The median (IQR) time in bed was 455 (108) minutes; the median mean activity score was 14 per epoch during sleep, which was also highly variable with an IQR of 14.
Week-to-week differences in time in bed were not significant (F 3,494 = 0.87, P = 0.45).
Sleep and menstrual cycle segment analysis
Sleep progressively worsened across the menstrual cycle, as characterized by lower sleep efficiency, shorter sleep time, and increased activity during sleep (Fig. 1) . The comparison of the second week and the third week was of interest, as the interaction of two segments approximated the midcycle node when the ovulatory event probably occurred ( Table 2 ).
The total activity score progressively increased during the menstrual cycle and culminated in much greater activity score variability on the fourth week (Fig. 1C) . The IQR for the fourth week was 14.73, which was 16.72% higher than that for the second week (IQR, 12.62) and 18.98% higher than that for the third week (IQR, 12.38). The mean width of the 95% CIs for the second, third, and fourth weeks were 2.44, 3.16, and 5.16, respectively. All pairwise comparisons of these bands were significant at P = 0.05.
Mean total sleep time, sleep efficiency, and mean activity score did not differ significantly between the second week and the third week. However, total sleep time tended to be 11.5 minutes longer on the third week compared with the second week (P G 0.07). In contrast, mean total sleep time and sleep efficiency were significantly different between the third week and the fourth week. On average, total sleep time was 25 minutes shorter on the fourth week compared with the third week (P = 0.0002), resulting in a 5% lower sleep efficiency on the fourth week compared with the third week (P G 0.0001). The F statistics for the week-to-week mean comparisons were F 2,2879 = 7.08 (P = 0.0009) for total sleep time, F 2,2623 = 11.09 (P G 0.0001) for sleep efficiency, and F 2,2497 = 1.99 (P = 0.15) for mean activity score ( Table 2 ).
In statistical models that included health, social, and daily health behavior measures, menstrual cycle weeks were significantly associated with total sleep time and sleep efficiency with P G 0.0009 and P G 0.0001, respectively. Hot flashes and night sweats were not significant in any of the models. Notably, we observed interactions between menstrual cycle week and smoking for all three sleep measures, and between menstrual cycle week and several covariates from all three domains (health status, social dimensions, and health behaviors) of sleep efficiency (see Table A of Appendix II in the Supplemental Digital Content, http://links.lww.com/MENO/A99).
A significant interaction (P = 0.0031) between timing segment and smoking was observed for sleep efficiency ( Fig. 2A ).
Smokers and nonsmokers had similar sleep efficiencies on the third week (74.0% vs 79.6%), whereas smokers had markedly lower sleep efficiency than nonsmokers on the second week (69.2% vs 80.6%) and fourth week (65.0% vs 78.5%). Within the smoker group (and the nonsmoker group), sleep efficiency was significantly lower on the fourth week than on the third week with P = 0.02 and P = 0.04, respectively. However, no significant differences were observed between the second week and the third week (P 9 0.7). A significant interaction between week and BMI (P = 0.01) was observed for sleep efficiency (Fig. 2B ). Sleep efficiency for nonobese women (BMI G 30 kg/m 2 ) on the second, third, and fourth weeks was 81.3%, 82.14%, and 80.31%, respectively. For this group, sleep efficiency was significantly lower at premenstruation (ie, fourth week) than in the prior week. For obese women (BMI Q 30 kg/m 2 ), sleep efficiency on the second, third, and fourth weeks were 76.8%, 74.7%, and 73.3%, respectively, and premenstruation week 4 had the lowest sleep efficiency.
For total sleep time (Fig. 2C) , the interaction between week and smoking was also significant (P = 0.03). For nonsmokers, total sleep time on the second, third, and fourth weeks was 364.2, 365.0, and 357.6 minutes, respectively. Premenstruation week 4 had slightly shorter sleep time in contrast to the prior 2 weeks (P = 0.08). For smokers, total sleep time on the second, third, and fourth weeks was 324.6, 350.5, and 303.8 minutes, respectively. Premenstrual week 4 had markedly shorter sleep time (by about 50 min) compared with the previous week (P = 0.002).
The interaction between week and smoking for the mean activity score model was also significant (P = 0.003). Premenstruation week 4 had a slightly lower log mean activity score (2.6) than the second and third weeks (scores of 2.8 and 2.7, respectively). However, the coefficient of variation plot and the signal-to-noise ratio showed the largest variation (or the lowest signal-to-noise ratio) around day 14 and on the last week (see For all models of sleep efficiency, total sleep time, and mean activity score, the interaction effects on smoking, BMI, ethnicity, and alcohol consumption were not significant (data not shown).
DISCUSSION
The time series actigraphy data analysis 33 allowed us to evaluate variability in sleep profiles across the menstrual cycle. This analysis was performed using data from one menstrual cycle in 163 healthy menstruating women, with a mean (SD) cycle length of 25.9 (6.8) days, in the SWAN Sleep Study. Actigraphy-derived sleep measures demonstrated that sleep efficiency declined during the course of the cycle (Fig. 1B) , with the most prominent decrease on the fourth week (the premenstrual period). We observed less efficient sleep and shorter sleep durations in the final 7-day week of the menstrual cycle, a period in which progesterone and estradiol levels 1.3) , P G 0.0001 F 2,2623 = 11.09, P G 0.0001 log Mean activity score, counts 2.7 (0.1) 2.7 (0.1) 2.6 (0.1) 0.1 (0.07), P = 0.2 0.05 (0.08), P = 0.5 F 2,2497 = 1.99, P = 0.2 Data are presented as adjusted least-squares mean (SE). Covariates include chronological age, body mass index, site, race, difficulty paying for basics, menopause status, marital status, education, health history, perceived stress, apnea-hypopnea index, Inventory of Depressive Symptoms without sleep items, daily smoking, vasomotor symptoms, exercise, alcohol consumption, caffeine consumption, and sleep medication. decline. 34<36 In contrast, no parallel evidence of less favorable sleep around the approximate midcycle node was observed. Importantly, the study identified potentially important modifiable risk factors that influenced the menstrual segment's association with the sleep measures. Smoking, in particular, enhanced the relationship of the menstrual cycle with sleep efficiency and total sleep time.
Previous studies of sleep disruption using sleep electroencephalogram have reported changes in electroencephalogram power density in the 14.25-to 15.0-Hz band during nonYrapid eye movement sleep in association with changes in progesterone levels during the luteal phase of the menstrual cycle but have reported no significant variations in objective measures of visually scored sleep duration or continuity across the menstrual cycle. 37, 38 We tested the mean and slope differences in sleep measures between weekly segments of the menstrual cycle. The knots of each segment were determined based on assumptions about the timing of major shifts in reproductive hormone concentrations in regularly menstruating adult women. Significant differences in sleep efficiency and total sleep timeVbut not in time in bedVwere observed. Therefore, the change in sleep efficiency reflects decreased sleep time rather than increased time in bed.
Fluctuations in reproductive hormones seem to affect sleep throughout a woman's life span from adulthood to menopause. 39, 40 Ideally, we would have concurrent hormone measures to relate directly to the sleep measures and to corroborate the use of the time-based segments. Unfortunately, specimens of concurrent hormones were not collected because of collection cost, assay cost, and the ongoing daily burden on the study participants. However, an earlier report from the core SWAN suggested that the menstrual cycle pattern of increased urinary progesterone metabolite was associated with selfidentified increased trouble sleeping among perimenopausal women and that increased follicle-stimulating hormone (FSH) levels were associated with increased trouble sleeping among premenopausal women. 10 This association between increased progesterone (pregnanediol glucuronide) excretion and trouble sleeping contrasts with other studies suggesting that high progesterone levels facilitate sleep. 11 In the absence of hormone measures describing the LH surge and the rapid rise in progesterone, we assumed that ovulation occured at the midcyle and that comparisons of time segments were sufficiently sensitive to identify important changes in the sleep characteristics of the midcycle. 39 Our failure to observe changes in sleep measures between the second week and the third week may mean that ovulation itself did not influence sleep, that misclassification of the day of ovulation limited our ability to detect such an association, or that, for some women, changes were associated with marked decreases in progesterone and estradiol that occurred on the last week of the cycle. Had statistically significant midcycle differences been observed, factors other than changes in LH and progesterone levels might have been candidates for their contribution to sleep changes. For example, readily discernible changes in body temperature at the midcycle might be associated with alterations in sleep behaviors and need to be further explored. Notably, significant effects of hot flashes and night sweats on sleep were not observed in this study.
Importance of covariates in relation to menstrual cycle effects on sleep
Many sleep studies adjusted for the presence of covariates such as smoking or body size. Our data analyses suggest that these covariates, as well as race/ethnicity and financial strain, are important effect modifiers of our proxy measures (time segments) for pronounced hormone changes and explained contrasting findings. The potential for smoking to be an effect modifier of the hormonal effects on sleep is not surprising given previous research. Smoking has effects on various metabolic and biological processes in the body and has been associated with early menopause, 41<43 higher FSH levels, 44 and lower ovarian follicle density. 45 Potential mechanisms of smoking's toxic effects on the ovary include the effects of cigarette smoke on oocyte quantity, 46 oocyte quality, 47 and disruption of endocrine function, 48 or the effects of nicotine on sleep by acting on various neurotransmitter systems 49 and by reducing oxygen-carrying capacity. 50, 51 This study also showed that body massVin addition to smokingVaffected sleep quality. Both obese and nonobese women had significantly lower sleep efficiency in the premenstrual week than in the prior weeks. However, obese women had markedly lower sleep efficiency than nonobese women on the fourth week, which might have been attributable to the influence of body size on hormone patterns, 52 especially on FSH changes. 10, 53, 54 For example, nonobese women have a significantly faster rate of change in FSH levels and higher FSH levels during the menopausal transition. Sleep efficiency was significantly lower in women who had slower FSH change, 4 and FSH level was significantly positively related to trouble sleeping. 10 Change in estradiol levels was not related to sleep pathology. 4 Levels of estrone conjugates (E1c) and LH had no significant associations with trouble sleeping. 10 For this group of healthy women, we found that larger body size, higher AHI, greater financial strain, and smoking were associated with poorer sleep quality in the premenstrual phase. In contrast, hot flashes/cold sweats, stress, and depression did not seem to affect sleep in this phase specifically, as determined by the absence of segment-by-variable interactions. However, other studies have shown that women with severe premenstrual syndrome had poorer sleep quality in the premenstrual phase. 12, 38 
Impact of data loss
As noted above, the analysis excluded 7 days of data from the first week. To evaluate the potential impact of this type of data loss, we conducted a simulation study. The simulation showed that the intraclass correlation coefficient was 0.90 with 3 weeks of data (21 d) and 0.80 with second-and thirdweek data only (14 d) . Another simulation using PSG data showed that about 125 women gave a 95% coverage probability (ie, the proportion of simulation runs in which the estimated interval contained the true value of the parameter over all the simulation runs) to detect Bnight[ effects. 30 This suggests that the analytical data set (163 women with 3 wk of data) was of sufficient sample size to minimize estimation bias due to data loss by excluding some ineligible women and first-week data.
Strengths and limitations
This study had unique strengths. It was an in-home sleep study of substantial sample size that also included objective daily assessments of sleep duration across a menstrual cycle. This study was conducted in a sample of healthy middle-aged women to characterize the normal physiological and psychological events of menopause in relation to sleep, but care must be exercised in extrapolating these findings to studies directed toward samples or study designs that are highly enriched for sleep pathology (eg, a case-control study of insomnia). The SWAN Sleep Study was able to capitalize on the availability of a wide range of information on covariates from the core SWAN. The daily sleep diaries were developed to not only record when sleep began and ended but also to consider timevarying health behaviors as covariates, with day-to-day variations that could influence associations between menstrual cycle phase and sleep. Additional strengths of this study include the standardization of cycle length to account for unequal cycles 12, 28 and the use of semiparametric stochastic mixed-effects models 29 that took into account betweenwomen and within-woman effects with a flexible functional form (where linear or quadratic terms might be inappropriate).
Nonetheless, the study also had limitations. The availability of data from only one menstrual cycle precludes exploring potential cycle-to-cycle variations or periodic patterns in this specific age group. Because African-American women were recruited by three SWAN Sleep Study sites but only one site recruited Chinese women (a condition imposed by the design of the parent study), we could not disaggregate sources of variation associated specifically with study site and race/ ethnicity. Furthermore, the study had only 16 smokers; thus, smoking effects should be interpreted cautiously and confirmed in future studies.
The size of the differences between the third week and the fourth week was small to moderate for some outcomes, including mean activity counts and total sleep time. These findings are nevertheless important for understanding and furthering research on the etiology of sleep disturbances during midlifeVa significant problem for many women that has potential effects on health. Furthermore, we have previously reported that self-reported trouble sleeping was more prevalent in the premenstrual week, suggesting that the difference in total sleep time, on average, between the third week and the fourth week of the menstrual cycle has clinical significance. 10 
CONCLUSIONS
The profiles of two daily measures of sleep (sleep efficiency [%] and total sleep time [minutes]) and one measure of movement during sleep (mean activity score [counts]) differ across a 28-day menstrual cycle. There are no significant mean and slope differences between the second week and the third week (corresponding to the midcycle). Women sleep worse during the premenstrual period (fourth week), as quantified by shorter total sleep time and lower sleep efficiency. The presence of significant effect modifications indicates that there exist complex patterns between proxy measures of hormone status and lifestyle factors (such as smoking) or body size in relation to sleep.
